X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs NOVARTIS - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA NOVARTIS TORRENT PHARMA/
NOVARTIS
 
P/E (TTM) x 43.8 316.8 13.8% View Chart
P/BV x 6.2 35.1 17.6% View Chart
Dividend Yield % 0.8 1.3 63.6%  

Financials

 TORRENT PHARMA   NOVARTIS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
NOVARTIS
Mar-18
TORRENT PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,550758 204.5%   
Low Rs1,144579 197.5%   
Sales per share (Unadj.) Rs354.7228.4 155.3%  
Earnings per share (Unadj.) Rs40.131.7 126.3%  
Cash flow per share (Unadj.) Rs64.232.8 196.0%  
Dividends per share (Unadj.) Rs14.0010.00 140.0%  
Dividend yield (eoy) %1.01.5 69.5%  
Book value per share (Unadj.) Rs273.1297.1 91.9%  
Shares outstanding (eoy) m169.2224.69 685.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.82.9 129.7%   
Avg P/E ratio x33.621.1 159.5%  
P/CF ratio (eoy) x21.020.4 102.8%  
Price / Book Value ratio x4.92.2 219.2%  
Dividend payout %34.931.5 110.9%   
Avg Mkt Cap Rs m227,89716,505 1,380.8%   
No. of employees `00014.70.7 2,200.6%   
Total wages/salary Rs m11,3531,445 785.5%   
Avg. sales/employee Rs Th4,083.08,441.3 48.4%   
Avg. wages/employee Rs Th772.32,163.6 35.7%   
Avg. net profit/employee Rs Th461.31,173.1 39.3%   
INCOME DATA
Net Sales Rs m60,0215,639 1,064.4%  
Other income Rs m2,9881,718 173.9%   
Total revenues Rs m63,0097,357 856.4%   
Gross profit Rs m13,493-63 -21,588.0%  
Depreciation Rs m4,08625 16,150.2%   
Interest Rs m3,08555 5,578.3%   
Profit before tax Rs m9,3101,575 591.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,529792 319.4%   
Profit after tax Rs m6,781784 865.4%  
Gross profit margin %22.5-1.1 -2,028.1%  
Effective tax rate %27.250.3 54.0%   
Net profit margin %11.313.9 81.3%  
BALANCE SHEET DATA
Current assets Rs m52,6239,522 552.7%   
Current liabilities Rs m52,0223,296 1,578.3%   
Net working cap to sales %1.0110.4 0.9%  
Current ratio x1.02.9 35.0%  
Inventory Days Days12037 326.6%  
Debtors Days Days7628 268.2%  
Net fixed assets Rs m85,01646 184,817.8%   
Share capital Rs m846123 685.7%   
"Free" reserves Rs m45,3767,213 629.1%   
Net worth Rs m46,2227,336 630.0%   
Long term debt Rs m41,1150-   
Total assets Rs m142,43211,105 1,282.6%  
Interest coverage x4.029.5 13.6%   
Debt to equity ratio x0.90-  
Sales to assets ratio x0.40.5 83.0%   
Return on assets %6.97.6 91.7%  
Return on equity %14.710.7 137.4%  
Return on capital %14.222.2 63.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,58061 24,059.6%   
Fx outflow Rs m3,6003,630 99.2%   
Net fx Rs m10,980-3,570 -307.6%   
CASH FLOW
From Operations Rs m8,9421,610 555.4%  
From Investments Rs m-47,070687 -6,851.5%  
From Financial Activity Rs m34,174-2,677 -1,276.8%  
Net Cashflow Rs m-3,655-380 962.9%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.0 2.0 351.0%  
FIIs % 12.6 1.6 787.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 21.5 40.9%  
Shareholders   26,511 41,647 63.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   SHASUN PHARMA  WYETH LTD  ASTRAZENECA PHARMA  SUVEN LIFE  CIPLA  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 24, 2018 12:37 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS